Capstone Therapeutics Corp
OTC:CAPS

Watchlist Manager
Capstone Therapeutics Corp Logo
Capstone Therapeutics Corp
OTC:CAPS
Watchlist
Price: 0.7 USD -0.74% Market Closed
Market Cap: $5.8m

Capstone Therapeutics Corp
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Capstone Therapeutics Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Capstone Therapeutics Corp
OTC:CAPS
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Capstone Therapeutics Corp
Glance View

Market Cap
5.8m USD
Industry
Biotechnology

Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.

CAPS Intrinsic Value
Not Available

See Also

Back to Top